10 research outputs found
Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma
Synthesis and Charge Transport Properties of Redox-Active Nitroxide Polyethers with Large Site Density
Is upper lobe lymph node dissection necessary for patients with non-small cell lung cancers of the right middle lobe?
Computed tomographic image comparison between mediastinal and lung windows provides possible prognostic information in patients with small peripheral lung adenocarcinoma
Macâ2âbinding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
Abstract Despite reports of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection after achieving sustained virological response (SVR), only few studies have demonstrated the incidence of other (nonâHCC) malignancies. This study aimed to clarify the incidence, survival probability, and factors associated with malignancy, especially nonâHCC malignancies, in patients with chronic HCV infection after achieving SVR. In this retrospective study, records of 3580 patients with chronic HCV infection who achieved SVR following directâacting antiviral (DAA) treatment were analyzed. The cumulative postâSVR incidence of nonâHCC malignancies was 0.9%, 3.1%, and 6.8% at 1, 3, and 5 years, respectively. The survival probability for patients with nonâHCC malignancies was 99.1%, 78.8%, and 60.2% at 1, 3, and 5 years, respectively, and the rate was significantly lower than that for patients with HCC. The Cox proportional hazards regression model identified Macâ2âbinding protein glycan isomer (M2BPGi) cutoff index (COI) â„ 1.90 at baseline and â„ 1.50 at 12 weeks following DAA treatment as significant and independent factors associated with the postâSVR incidence of nonâHCC malignancies. Furthermore, patients with either M2BPGi COI â„ 1.90 at baseline or M2BPGi COI â„ 1.50 at SVR12 had a significantly higher risk of postâSVR incidence of nonâHCC malignancies than of HCC. Conclusion: M2BPGi measurements at baseline and SVR12 may help predict the postâSVR incidence of nonâHCC malignancies in patients with chronic HCV infection who achieved SVR following DAA treatment. Early identification of these patients is critical to prolong patient survival